drugset / Trial / NCT00319566
Heart and Estrogen-Progestin Replacement Study (HERS)
Phase 3
Completed
2430 enrolled
University of California, San Francisco
Wyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedSingle-groupDouble-blindPrevention
Summary
The purpose of the study is to determine whether hormone replacement therapy in post menopausal women with coronary artery disease prevents future heart attacks or death from coronary heart disease.
Timeline
- Start
- 1992-07
- Primary completion
- —
- Completion
- 2001-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | conjugated estrogens | Other / unclassified | 0.625 mg | — |
| Subject | medroxyprogesterone acetate | Other / unclassified | 2.5 mg | — |